Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Immunovant, Inc. (IMVT) reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.See the Zacks Earnings Calendar to stay ahead of market-making news. IMVT’s Q3 Results in DetailResearch and development (R&D) expenses totaled $97. ...